key: cord-0691728-eqd8gy4y
authors: Sahney, Amrish; Wadhawan, Manav; Agarwal, Nitesh; Berry, Neha; Dadwal, Vishav; Vardani, Anil; Kumar, Ajay
title: A case series of amoebic liver abscess in patients with COVID-19 infection
date: 2021-10-29
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2021.10.146
sha: 1bf90b1e5138ce2eec6f5e24da18d8e2d9f959ec
doc_id: 691728
cord_uid: eqd8gy4y

BACKGROUND: Globally amoebiasis is the second leading cause of death due to parasitic diseases. Amoebic liver abscess (ALA) as an opportunistic infection in recently recovered COVID 19 disease patients has not been reported earlier. METHODS: We present here case series of 13 patients of ALA admitted during the month of May 2021 in BLK hospital, New Delhi and had recently recovered from COVID 19 disease. RESULTS: Out of 13, eight patients had moderate and one had severe COVID 19 disease. All these patients had received steroids for management of COVID 19 disease. Rest of 4(30%) patients had mild disease. The mean age of our patients was 50 years (37-81 years). Out of 13 patients, nine (70%) were male, 5 were diabetic, 2 were hypertensive and none were alcoholic. The most common presentation was fever (11/13) followed by pain upper abdomen (10/13). The mean time of symptom (fever or pain abdomen) onset from COVID 19 positivity date was 19 days (range 15-23 days). Complication in form of localised intra-peritoneal rupture was common in these patients and was seen in more than 50% (7/13) of patients. All the patients were managed with IV Metronidazole and abscess aspiration. All the patients were discharged and mean hospital stay was 6.6 days. CONCLUSION: We report here increase in incidence of ALA in recently recovered COVID 19 patients and propose that it is most likely due alteration in immune state of these patients. It is important for physicians to investigate for liver abscess in patients who presents again with fever and/or pain abdomen within 2 weeks of COVID 19 recovery.

Amoebiasis is the second leading cause of death due to parasitic diseases, leading to deaths of about 40,000-100,000 people per year globally. 1 It is endemic in Indian subcontinent. Entamoeba histolytica has a 2-stage life cycle that consists of an infectious cystic and a motile trophozoite stage. 2 The infection occurs via faeco-oral route through ingestion of cyst. Excystation occurs in small intestine, resulting in release of trophozoites and colonization of terminal ileum/caecum area.

In 90% of infected patients, trophozoites are encysted and passed in stools, other 10% penetrate and invade the colonic mucosal barrier, leading to tissue destruction and secretory bloody diarrhoea. In addition, trophozoites can spread hematogenously via portal circulation to the liver or even to more distant organs. Amoebic liver abscess is the most common extra-intestinal manifestation of this protozoan. 2 The ongoing pandemic of COVID 19 disease has affected more than 170 million people all over the world. 3 Also it is now known that secondary bacterial and other viral infections lead to recurrent admissions, increased morbidity and mortality of affected patients. 4 The second wave of COVID 19 disease in India was much larger than the first, the daily count on April 15, 2021 itself was double of the first peak. The new virus strain Delta is more infective and lead to increase in number of moderate to severe COVID 19 disease.

Although India continues to achieve stability over the existing situation, reported incidence of fungal infections has increased in patients who recovered from COVID 19 disease. 5 We noticed an increase in the number of admissions of patients with amoebic liver abscess in our hospital in the month of May 2021. We planned a retrospective analysis of these patients admitted with us during this period.

We analysed the hospital admission records for all patients admitted with a diagnosis of Amoebic We present the case series of these 13 patients of amoebic liver abscess who recently recovered from COVID19 disease.

The demographic, clinical, serological and imaging profiles of these 13 patients were recorded ( Table 1) . Out of 13 patients, eight had moderate and one patient had severe COVID 19 disease.

All patients with moderate & severe disease (9 out of 13) received steroids for management of COVID19 pneumonia. None of the patient received tocilizumab for the management of COVID-19. Four patients had mild infections and were managed as outpatient. None of the patients with mild disease received steroids.

All the patients had imaging evidence of liver abscess on USG abdomen and/or CT triple phase abdomen with positive amoebic serology and negative pus cultures from the abscess aspirate. The mean age of our patients was 50 years (37-81 years). Out of 13 patients, nine (70%) were male, 5 were diabetic, 2 were hypertensive and none were alcoholic. The most common presentation was fever (11/13) followed by pain upper abdomen (10/13). Two patients were incidentally detected to have liver abscess on usg abdomen, out of these two, one had unexplained rise in total leucocyte count and the other patient presented with altered stool colour. The mean time of symptom (fever or pain abdomen) onset from COVID 19 positivity date was 19 days (range 15-23 days).

The size of liver abscesses varied from the largest being 400cc and the smallest 60 cc respectively.

Nine out of 13 patients had solitary liver abscess out of which five had left lobe liver abscess.

Complication in form of localised intra-peritoneal rupture was common in these patients and was seen in seven out of 13 patients. Four of these 7 patients had solitary left lobe abscesses and rest of the 3 had bilobar abscesses (Fig1). Caecal involvement in CT triple phase abdomen was seen in three patients.

All the patients were treated with I.V. metronidazole and USG guided liver abscess aspiration. In seven patients with complicated liver abscess percutaneous catheter drainage was done and in rest of six single time aspiration. All the patients recovered and were discharged from hospital. Mean hospital stay was 6.6 days (range 5-14 days).

Our case series highlights the possibility of a correlation between COVID-19 and amoebic liver abscess. The number of patients admitted for ALA was much higher in May 2021 compared to the previous 6 months as well as in May 2020. Most of these patients (13 of 16) had recently recovered from COVID infection thus raising a suspicion that COVID 19 predisposes to development of ALA. Four out of 13 patients had mild COVID19 disease (and did not receive steroids), other 9 had received steroids for COVID 19 related complications. We postulate that the predisposition to develop ALA may be related to COVID 19 itself, and may be accentuated by the use of steroids.

The complication rate in these patients was also observed to be higher (more than 50% presented with localised rupture). This may be attributable to the steroid use (due to COVID 19) which may have masked the initial symptoms leading to late presentation.

Both innate and cell mediated immunity play significant role in pathogenesis of amoebic liver abscess. The risk factors for amoebic liver abscess are alcoholism, male sex with age 18-50 years, malnourishment, thymectomy and splenectomy, diabetics, corticosteroid use and altered cell mediated immunity like HIV infection. 6, 7 Recent data suggests that COVID 19 disease leads to suppression of cell mediated and innate immunity. SARS COV2 infection is associated with lymphopenia in moderate and severe cases. In recent studies the counts of CD8 + T, memory CD4 + T cells and Treg cells were shown to be decreased. 8

In addition, functional exhaustion of T cells has been reported in COVID-19 patients as indicated by upregulation of exhaustion markers, including PD-1, CTLA-4, TIGIT, and TIM-3 and downregulation of IFN-γ, TNF-α, granzyme B, and IL-2. 9 The recent randomized control trial reported decrease in mortality of patients of COVID 19 disease who were on oxygen support with use of dexamethasone. 10 Gluoco-corticosteroid leads to peripheral neutrophilia, inhibits release of cytokines and chemokines and impairs leucocyte migration site of inflammation. It also leads to lymphopenia (T cells more than B cells). This may have contributed to the higher complication rate in the patient's developing ALA in our cohort.

Both SARS-COV2 infection and use of glucocorticoids leads to suppression of immune system. This immunosuppressed state may lead to opportunistic infections in patients of COVID19 disease.

Treating clinicians need to be aware of the possibility of these infections and should rationalize the use of corticosteroids. First four weeks from the date of COVID 19 positivity are important, as all the patients of amoebic liver abscess presented during this time period in our study.

We hypothesize that increase in incidence of amoebic liver abscess in our hospital was most likely due to the alterations in the immune state in patients of COVID 19 disease. It is important for physicians to investigate for liver abscess in patients who presents again with fever and/or pain abdomen within 2 weeks of COVID 19 recovery. It will be interesting to see data from other centres in near future.

COVID-19 Weekly Epidemiological Update

The role of co-infections and secondary infections in patients with COVID-19

Cell-mediated immunity in patients with amoebic abscess of the liver

Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Dexamethasone in Hospitalized Patients with Covid-19

J o u r n a l P r e -p r o o f